Emergent Key Catalysts To Drive Upside

EMGE: Emergent Health logo
EMGE
Emergent Health

Submitted by David Gould as part of our contributors program.

As major companies like Pfizer (PFE) come off patent cliffs, healthcare investors ought to consider other emerging alternatives. Regenerative medicine specialist Emergent Health Corp (EMGE.PK) continues to be undervalued on several layers. From targeting positive secular trends to launching key catalysts, Emergent is well positioned for upside momentum. Their JDI International distributional network has reportedly seen double-digit growth, according to management, and above industry-average retainment. Demand has been so successful that unaudited sales in the first quarter were preliminarily estimated at nearly $500K, an up to 600% increase from one year ago. The launch of MultVitamin-MultiMineral with Stem Cell Nutrition and added Vitamin D was a major catalyst in achieving this phenomenal growth and, fortunately, the company has a favorable pipeline ahead.

There are several products, like MultVitamin-MultiMineral, that are likely to achieve the same kind of momentum. But, first, it is important to emphasize that Emergent is worth just $3.45M, which indicates a low multiple against unaudited preliminary sales. If sales momentum continues to grow like it has reportedly done, at some point, the market will begin to react. Emergent has had little volatility over the recent year, so it is vulnerable to dramatic swings in shareholder value at a beta of 3.3. Catalysts, listed below, will help to limit the downside and improve the upside for favorable risk/reward.

Relevant Articles
  1. Beating S&P500 BY 11% YTD, What To Expect From Travelers Stock?
  2. Up 50% Over The Last 12 Months, Is Hyatt Stock Still Attractive?
  3. Capital One Stock Gained 44% In The Last 6 Months, What’s Next?
  4. Up 8% Year To Date As 5G Gains Traction, What’s Next For Verizon Stock?
  5. Up 32% In The Last 12 Months, Where Is BNY Mellon Stock Headed?
  6. Rallying 30% YTD, What’s Spurring The Rally In Applied Materials’ Stock?

Vita-Stim Stem Cell

Vita-Stim Stem Cell Nutrition is a new product that helps increase the release of adult stem cells, or progenitor cells. Its efficacy has been scientifically backed by research that shows how its derivations can increase adult stem cell count and repair organs. This process may help counter the natural aging process. As the baby boomer population hits retirement, one could only imagine the kind of demand that Emergent will receive.

Infinity Anti-Aging

As the name suggests, Infinity Anti-Aging targets a similar market that Vita-Stim Stem Cell does. This product is a patented and patent pending formula that supports the increase in life span through activating SIRT-1 anti-aging genes. By encouraging the production of new cells with longer telomeres, Infinity Anti-Aging is believed to have effects that reverse the aging process. Biologists have discovered that telomeres decrease as animals get older, so increasing their length may extend life. Powerful 750 mg capsules of these products can impure digestion, awaken dormant adult stem cells in bone marrow, and stabilize liver cell membranes, among other groundbreaking effaces.

Hungarest Diet & Energy

Weight loss drugs have been all the craze of late. The FDA’s approval of two anti-obesity drugs from Arena and VIVUS each drove shareholder value sky high. But Emergent already has a product that targets a similar market. The product works by curbing the appetite. It helps regulate the chemical mechanism through controlling both appetite in the brain and stomach. It is currently distributed through Health Food Stores, and more distribution would go a long way in improving awareness and driving greater volumes.

Emergent 02 Water Oxygenator

This product helps oxygenate blood cells to detoxify and eliminate wastes. When water is infused with oxygen, it is absorbed into the blood stream upon consumption. The result is improved energy, greater vitality in the immune system, and a production of weight loss through fat burning.

Disclaimer: The distributor of this research report, Gould Partners, is not a licensed investment adviser or broker dealer. We are a consultant to Emergent Health and have been contracted ten thousand dollars. Investors are cautioned to perform their own due diligence as information contained within this report has been derived from public sources and cannot be guaranteed by us to be fully accurate. Always discuss investments with a licensed professional before making any financial decision. Statements made herein are often “forward-looking statements” as defined under Section 27A of the Securities Act of 1933, Section 21E of the Securities Act of 1934, and the Private Securities Litigation Reform Act of 1995. Since these statements are uncertain, actual results may be materially different from those expected.